GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Cash From Discontinued Investing Activities

AIM ImmunoTech (LTS:0A4Y) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Cash From Discontinued Investing Activities?

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

AIM ImmunoTech's cash from discontinued investing activities for the three months ended in Sep. 2024 was $0.00 Mil. It means AIM ImmunoTech received $0.00 Mil from discontinued investing activities. AIM ImmunoTech's cash from discontinued investing activities for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

AIM ImmunoTech Cash From Discontinued Investing Activities Historical Data

The historical data trend for AIM ImmunoTech's Cash From Discontinued Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Cash From Discontinued Investing Activities Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash From Discontinued Investing Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash From Discontinued Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

AIM ImmunoTech Cash From Discontinued Investing Activities Calculation

Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cash From Discontinued Investing Activities for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AIM ImmunoTech Cash From Discontinued Investing Activities Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Cash From Discontinued Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Cash From Discontinued Investing Activities
Comparable Companies
TRAW SNSE NLSP PMCB INTI OTLC NKGN LYRA JAGX HSTC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
AIM:USA HXB2:Germany
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
Website
https://www.aimimmuno.com
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Headlines

No Headlines